国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
International Medicine and Health Guidance News
2015年
17期
2588-2589,2591
,共3页
替莫唑胺%全脑放疗%非小细胞肺癌%脑转移瘤
替莫唑胺%全腦放療%非小細胞肺癌%腦轉移瘤
체막서알%전뇌방료%비소세포폐암%뇌전이류
Temozolomide%Whole-brain radiotherapy%Non-small cell lung cancer%Brain metastases
目的 观察替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移患者的临床疗效及安全性.方法 回顾分析了确诊非小细胞肺癌脑转移的患者32例,予以常规分割性全脑放疗,剂量DT 40 Gy (2Gy,1次/d,每周5d),放疗期间每日口服替莫唑胺75 mg,/(m2·d),放疗结束后每4周予以替莫唑胺200 mg/ (m2·d)口服5d方案化疗,共6周期.生存率使用Kaplan-Meier方法计算.结果 32例患者均可评价疗效,其中完全缓解5例(15.6％),部分缓解19例(59.3％),稳定4例(12.5％),进展4例(12.5％),近期治疗有效率74.9％,临床获益率87.4％,中位生存期7.6个月.治疗的不良反应主要表现为胃肠道症状、骨髓抑制,患者均可耐受.结论 替莫唑胺联合全脑放疗方案治疗非小细胞肺癌脑转移患者有较好的近期疗效及安全性,值得在临床进一步使用.
目的 觀察替莫唑胺聯閤全腦放療治療非小細胞肺癌腦轉移患者的臨床療效及安全性.方法 迴顧分析瞭確診非小細胞肺癌腦轉移的患者32例,予以常規分割性全腦放療,劑量DT 40 Gy (2Gy,1次/d,每週5d),放療期間每日口服替莫唑胺75 mg,/(m2·d),放療結束後每4週予以替莫唑胺200 mg/ (m2·d)口服5d方案化療,共6週期.生存率使用Kaplan-Meier方法計算.結果 32例患者均可評價療效,其中完全緩解5例(15.6％),部分緩解19例(59.3％),穩定4例(12.5％),進展4例(12.5％),近期治療有效率74.9％,臨床穫益率87.4％,中位生存期7.6箇月.治療的不良反應主要錶現為胃腸道癥狀、骨髓抑製,患者均可耐受.結論 替莫唑胺聯閤全腦放療方案治療非小細胞肺癌腦轉移患者有較好的近期療效及安全性,值得在臨床進一步使用.
목적 관찰체막서알연합전뇌방료치료비소세포폐암뇌전이환자적림상료효급안전성.방법 회고분석료학진비소세포폐암뇌전이적환자32례,여이상규분할성전뇌방료,제량DT 40 Gy (2Gy,1차/d,매주5d),방료기간매일구복체막서알75 mg,/(m2·d),방료결속후매4주여이체막서알200 mg/ (m2·d)구복5d방안화료,공6주기.생존솔사용Kaplan-Meier방법계산.결과 32례환자균가평개료효,기중완전완해5례(15.6％),부분완해19례(59.3％),은정4례(12.5％),진전4례(12.5％),근기치료유효솔74.9％,림상획익솔87.4％,중위생존기7.6개월.치료적불량반응주요표현위위장도증상、골수억제,환자균가내수.결론 체막서알연합전뇌방료방안치료비소세포폐암뇌전이환자유교호적근기료효급안전성,치득재림상진일보사용.
Objective To observe the therapeutic effect and toxicity of temozolomide combined with whole-brain radiotherapy in the treatment of non-small cell lung cancer complicated with metastatic brain tumor.Methods 32 patients with non-small cell lung cancer who were diagnosed with brain metastases orally took temozolomide (75mg/m2·d) and received 40 Gy fractionated conventional external-beam radiotherapy (2 Gy per day,5 days per week) for 4 weeks.After radiotherapy,patients took temozolomide (200mg/m2·d) for 5 days every 4 weeks for 6 cycles.Progression-free survival curves and overall were estimated by Kaplan-Meier technique.Results All the 32 patients were evaluable for response with 5 cases of CR,19 PR,4 SD,and 4 PD.The overall response rate was 74.9％ and the clinical benefit rate was 87.4％.The median progression-free survival time was 7.6 months.The main side effects were gastrointestinal reaction and myelosuppression,which were alleviated by symptomatic treatment.Conclusions Temozolomide combined with whole-brain radiotherapy is effective with mild toxicity for patients with non-small cell lung cancer who were diagnosed with brain metastases.
